Home › Portola Reports Q4, Updates Business Plans: Analysis Of This High-Risk Play
 

Keywords :   


Portola Reports Q4, Updates Business Plans: Analysis Of This High-Risk Play

2016-03-02 23:40:43| Biotech - Topix.net

I first bought and wrote about Portola Pharmaceuticals in mid-2014, when the stock was revisiting its brief peak around $30 that it first hit in September 2013. It had IPO'ed in May at $15, so Friday's closing price of $27.79 still represents a successful IPO.

Tags: business play reports analysis

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.05Mary Kay Inc. Expands into Denmark
03.05Hotel Collection Teams with Lucasfilm to Create Scented Universe for National Star Wars Day
03.05This Week in Waste: Top Stories April 29 May 2, 2024
03.05FENC Uncaps Major Success with Global Sustainable Expansion in Recycled Polyester
03.05Klamath Falls, OR. Receives Funds to Improve Water Recycling Quality, Supply
03.05Walmart to use Generative AI to Help Reduce Food Waste in Stores
03.05FCC Environmental Services Expands Midwest Presence, Compressed Natural Gas Operations
03.05Farm Progress America, May 3, 2024
More »